Brainsway reports favorable coverage for accelerated deep TMS

Brainsway Ltd. (TASE:BRIN), a developer of innovative neuromodulation solutions, has announced favorable coverage decisions for its accelerated deep TMS (aTMS) system in several key markets. The company reported that the system has received coverage approval from multiple U.S. health insurers, including Aetna and Cigna, for the treatment of major depressive disorder in adult patients who have not responded to prior antidepressant therapies [引用越界:1]. This development is expected to enhance patient access to the non-invasive treatment and potentially drive increased adoption of the technology.

The aTMS system, which received FDA clearance in 2021, is designed to deliver focused magnetic pulses to deeper brain regions more efficiently than traditional TMS systems. Brainsway noted that the recent coverage decisions follow successful clinical trials and growing clinical evidence supporting the efficacy of aTMS in treating depression.

Analysts suggest that the expanded coverage could support Brainsway’s revenue growth and market expansion, particularly as demand for non-pharmacological mental health treatments continues to rise. The company has not disclosed specific financial projections related to the coverage decisions.